Abstract
The most common primary liver malignancy, hepatocellular carcinoma (HCC), has a high likelihood of mortality, and much effort into early detection and treatment has occurred. Multiple staging systems have surfaced of which some guide treatment. Curative intent is a goal of early-staged HCC treatment, and this can be achieved with surgical resection, liver transplantation, and minimally invasive percutaneous therapies such as tumor ablation. Many of the newer ablation techniques have evolved from shortcomings of prior methods which have resulted in an expanded number of applications for tumor ablation. Our review focuses on current mainstream image-guided percutaneous ablation modalities which are commonly performed as an alternative to surgery.
Similar content being viewed by others
References
Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from, to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 1990;2017:1683–1691.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma; The BCLC staging classification. Semin Liver Dis. 1999;19:329–338.
Forner A, Reig M, Rodriguez de Lope C, Bruix J. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.
Habib A, Desai K, Hickey R, et al. Locoregional therapy of hepatocellular carcinoma. Clin Liver Dis. 2015;19:401–420.
Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–380.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
Livraghi T, Bolondi L, Lazzaroni S, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis: A study on 207 patients. Cancer. 1992;69:925–929.
Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology. 1995;197:101–108.
Dodd GD, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: At the threshold of a major breakthrough. Radiographics. 2000;20:9–27.
Lencioni R, Crocetti L, Della Pina C, Cioni D. Image-Guided Ablation of Hepatocellular Carcinoma. In: Geschwind JFH, Soulen MC, eds. Interventional Oncology, Principle and Practice. New York, NY: Cambridge University Press; 2008:145–159.
Koda M, Murawaki Y, Mitsuda A, et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer. 2000;88:529–537.
Lencioni R, Bartolozzi C, Caramella D, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: Analysis of prognostic factors in 105 western patients. Cancer. 1995;76:1737–1746.
McWilliams JP, Yamamoto S, Raman SS, et al. Percutaneous ablation of hepatocellular carcinoma: Current status. J Vasc Interv Radiol. 2010;21:S204–S213.
Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–240.
McGahan J, Browning PD, Brock JM, Tesluk H. Hepatic ablation using radiofrequency electrocautery. Invest Radiol. 1990;25:267–270.
Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance. Am J Roentgenol. 2000;174:323–331.
Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology. 2000;217:633–646.
Okusaka T, Okada S, Ueno H, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931–1937.
Salmi A, Turrini R, Lanzani G, Savio A, Anglani L. Efficacy of radiofrequency ablation of hepatocellular carcinoma associated with chronic liver disease without cirrhosis. Int J Med Sci. 2008;5:327–332.
Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the milan criteria. Ann Surg. 2010;252:903–912.
Lee HW, Lee JM, Yoon JH, et al. A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma. Ann Surg Treat Res. 2018;94:74–82.
Fang Y, Chen W, Liang X, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:193–200.
Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology. 2000;214:761–768.
Huffman SD, Huffman NP, Lewandowski RJ, Brown DB. Radiofrequency ablation complicated by skin burn. Semin Intervent Radiol. 2011;28:179–182.
Goldberg SN, Solbiati L, Halpern EF, Gazelle GS. Variables affecting proper system grounding for radiofrequency ablation in an animal model. J Vasc Intervent Radiol. 2000;11:1069–1075.
Patterson EJ, Scudamore CH, Owen DA, Nagy AG, Buckowski AK. Radiofrequency ablation of porcine liver in vivo effects of blood flow and treatment time on lesion size. Ann Surg. 1998;227:559–565.
Bhardwaj N, Strickland AD, Ahmad F, Ataneysan L, West K, Lloyd DM. A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver. Pathology. 2009;41:168–172.
Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT Jr. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236:132–139.
Tabuse K. A new operative procedure of hepatic surgery using a microwave tissue coagulator. Arch Jap Chir. 1979;48:160–172.
Murakami R, Yoshimatsu S, Yamashita Y, Matsukawa T, Takahashi M, Sagara K. Treatment of hepatocellular carcinoma: Value of percutaneous microwave coagulation. Am J Roentgenol. 1995;164:1159–1164.
Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: Principles and applications. RadioGraphics. 2005;25:S69–S83.
Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver ablation: Best practice. Radiol Clin N Am. 2015;53:933–971.
Wright SW, Lee FT Jr, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10:275–283.
Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma long-term outcome and prognostic factors. Cancer. 2009;115:1914–1923.
Llang P, Dong B, Yu X, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005;235:299–307.
Dong B, Liang P, Yu X, et al. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: Results in 234 patients. Am J Roentgenol. 2003;180:1547–1555.
Xu L-F, Sun H-L, Chen Y-T, et al. Large primary hepatocellular carcinoma: Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28:456–463.
Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol. 2018;24:219–224.
Cooper IS. Cryogenic surgery. A new method of destruction or extirpation of benign or malignant tissues. N Engl J Med. 1963;268:743–749.
Ravikumar TS, Kane R, Cady B, Jenkins R, Clouse M, Steele G Jr. A 5-year study of cryosurgery in the treatment of liver tumors. Arch Surg. 1991;126:1520–1524.
Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology. 2011;258:351–369.
Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37:171–186.
Permpongkosol S, Sulman A, Solomon SB, Gong GX, Kavoussi LR. Percutaneous computerized tomography guided renal cryoablation using local anesthesia: Pain assessment. J Urol. 2006;176:915–918.
Allaf ME, Varkarakis IM, Bhayani SB, Inagaki T, Kavoussi LR, Solomon SB. Pain control requirements for percutaneous ablation of renal tumors: Cryoablation versus radiofrequency ablation—initial observations. Radiology. 2005;237:366–370.
Gilbert JC, Onik GM, Hoddick WK, et al. Real time ultrasonic monitoring of hepatic cryosurgery. Cryobiology. 1985;22:319–330.
Lee FT Jr, Chosy SG, Littrup PJ, Warner TF, Kuhlman JE, Mahvi DM. CT-monitored percutaneous cryoablation in a pig liver model: Pilot study. Radiology. 1999;211:687–692.
Silverman SG, Sun MR, Tuncali K, et al. Three-dimensional assessment of MRI-guided percutaneous cryotherapy of liver metastases. Am J Roentgenol. 2004;183:707–712.
Weber SM, Lee FT Jr, Warner TF, Chosy SG, Mahvi DM. Hepatic cryoablation: US monitoring of extent of necrosis in normal pig liver. Radiology. 1998;207:73–77.
Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg. 1999;23:109–114.
Xu K-C, Niu L-Z, Zhou Q, et al. Sequential use of transarterial chemoembolization and percutaneous cryosurgery for hepatocellular carcinoma. World J Gastroenterol. 2009;15:3664–3669.
Davalos RV, Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–231.
Lee EW, Chen C, Prieto VE, Dry SM, Loh CT, Kee ST. Advanced hepatic ablation technique for creating complete cell death: Irreversible electroporation. Radiology. 2010;255:426–433.
Seror O. Ablative therapies: Advantages and disadvantages of radiofrequency, cryotherapy, microwave and electroporation methods, or how to choose the right method for an individual patient? Diagn Interv Imaging. 2015;96:617–624.
Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Inter Radiol. 2014;25:112–118.
Sutter O, Calvo J, N’Kontchou G, et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: A retrospective single-center case series. Radiology. 2017;284:877–886.
Cornelis FH, Durack JC, Kimm SY, et al. A comparative study of ablation boundary sharpness after percutaneous radiofrequency, cryo-, microwave, and irreversible electroporation ablation in normal swine liver and kidneys. Cardiovasc Intervent Radiol. 2017;40:1600–1608.
Niessen C, Beyer LP, Pregler B, et al. Percutaneous ablation of hepatic tumors using irreversible electroporation: A prospective safety and midterm efficacy study in 34 patients. J Vasc Inter Radiol. 2016;27:480–486.
Niessen C, Thumann S, Beyer L, et al. Percutaneous irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017;7:1–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conlict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bailey, C.W., Sydnor, M.K. Current State of Tumor Ablation Therapies. Dig Dis Sci 64, 951–958 (2019). https://doi.org/10.1007/s10620-019-05514-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-019-05514-9